Vascular endothelial growth factor (VEGF) may be a useful biomarker to identify osteosarcoma patients whose tumors may be most likely to respond proteasome inhibitors, given that serum levels of VEGF in osteosarcoma patients correlate well with intra-tumoral levels [71]. This evidence concerns the gene VEGFA and osteosarcoma.